PMID- 35747720
OWN - NLM
STAT- MEDLINE
DCOM- 20220627
LR  - 20231221
IS  - 1687-5273 (Electronic)
IS  - 1687-5265 (Print)
VI  - 2022
DP  - 2022
TI  - Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in 
      Allergic Rhinitis Complicated with Diabetes.
PG  - 6935758
LID - 10.1155/2022/6935758 [doi]
LID - 6935758
AB  - The prevalence of allergic rhinitis has exhibited an upward trend, and diabetes 
      is a common endocrine metabolic disorder. Treatment of allergic rhinitis 
      complicated with diabetes has been marginally explored. This study aimed to 
      observe the effect of rupatadine fumarate combined with acupoint application in 
      the treatment of allergic rhinitis complicated with diabetes and its effect on 
      serum IgE levels. Totally 80 patients with allergic rhinitis complicated with 
      diabetes admitted to our hospital from December 2019 to December 2020 were 
      recruited and assigned to receive either rupatadine fumarate (control group) or 
      rupatadine fumarate plus acupoint application (research group). The clinical 
      observation indexes of the two groups of patients before and after treatment were 
      analyzed, and the clinical efficacy of the two groups was evaluated. Rupatadine 
      fumarate plus acupoint application was associated with a significantly higher 
      efficacy (23 cases of markedly effective, 14 cases of effective, and 3 cases of 
      ineffective) versus rupatadine fumarate alone (14 cases of markedly effective, 16 
      cases of effective, and 10 cases of ineffective) (chi (2) = 4.501, p = 0.034). The 
      immunoglobulin E (IgE) and nasal mucosal eosinophils (EOS) levels of the two 
      groups of patients after treatment decreased significantly, and the research 
      group had lower results (p < 0.05). Patients in the research group showed 
      significantly lower syndrome scores than those in the control group (p < 0.05). 
      Rupatadine fumarate plus acupoint application resulted in significantly lower 
      physical sign scores and interleukin-4 (IL-4) levels and higher levels of 
      interferon-gamma (INF-gamma) versus rupatadine fumarate alone (p < 0.05). The two 
      groups showed a similar incidence of adverse events (p > 0.05). Rupatadine 
      fumarate plus acupoint application may offer a viable alternative for the 
      treatment of allergic rhinitis as it alleviates the clinical symptoms, improves 
      the treatment efficiency, and enhances the anti-allergic effect of the drug, with 
      a high safety profile.
CI  - Copyright (c) 2022 Yu Liu et al.
FAU - Liu, Yu
AU  - Liu Y
AD  - Department of Otolaryngology, Nanjing Integrated Traditional Chinese and Western 
      Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing 
      210014, China.
FAU - Jiang, Pengjun
AU  - Jiang P
AD  - Department of Hematology, Affiliated Hospital of Nanjing University of Chinese 
      Medicine, Nanjing 210029, China.
FAU - Chen, Xuqing
AU  - Chen X
AD  - Department of Otolaryngology, Affiliated Hospital of Nanjing University of 
      Chinese Medicine, Nanjing 210029, China.
FAU - Zhang, Wen
AU  - Zhang W
AD  - Department of Otolaryngology, Affiliated Hospital of Nanjing University of 
      Chinese Medicine, Nanjing 210029, China.
FAU - Shi, Jun
AU  - Shi J
AUID- ORCID: 0000-0002-6911-6381
AD  - Department of Otolaryngology, Affiliated Hospital of Nanjing University of 
      Chinese Medicine, Nanjing 210029, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220614
PL  - United States
TA  - Comput Intell Neurosci
JT  - Computational intelligence and neuroscience
JID - 101279357
RN  - 0 (Fumarates)
RN  - 2AE8M83G3E (rupatadine)
RN  - 2YHB6175DO (Cyproheptadine)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
RIN - Comput Intell Neurosci. 2023 Dec 13;2023:9803914. PMID: 38124823
MH  - Acupuncture Points
MH  - Cyproheptadine/analogs & derivatives
MH  - *Diabetes Mellitus
MH  - Fumarates/therapeutic use
MH  - Humans
MH  - Immunoglobulin E/therapeutic use
MH  - *Rhinitis, Allergic/complications/drug therapy
MH  - *Rhinitis, Allergic, Seasonal/drug therapy
PMC - PMC9213154
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/06/25 06:00
MHDA- 2022/06/28 06:00
PMCR- 2022/06/14
CRDT- 2022/06/24 02:18
PHST- 2022/03/07 00:00 [received]
PHST- 2022/04/22 00:00 [revised]
PHST- 2022/05/07 00:00 [accepted]
PHST- 2022/06/24 02:18 [entrez]
PHST- 2022/06/25 06:00 [pubmed]
PHST- 2022/06/28 06:00 [medline]
PHST- 2022/06/14 00:00 [pmc-release]
AID - 10.1155/2022/6935758 [doi]
PST - epublish
SO  - Comput Intell Neurosci. 2022 Jun 14;2022:6935758. doi: 10.1155/2022/6935758. 
      eCollection 2022.